AstraZeneca Forms Research Alliance In China For Chronic Kidney Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
To bring new treatment for 112 million patients with kidney disease in China, AstraZeneca is establishing a research collaboration with Shenzhen University to discover new medicines for diabetic nephropathy.